XETRA · CNW.DE
co.don AG
€0.25€0.00 (0.0%)
co.don AG’s quoted price sits in the lower half of its reported 52-week range, 89.57% below the high.
Loading market information…
XETRA · MDG1.DE · EUR
Stock price, earnings
Quote as of Apr 29, 2025, 03:36 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Medigene AG’s quoted price sits in the lower half of its reported 52-week range, 96.79% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Medigene AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:12 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2021 |
|---|
| Dec 31, 2021 |
| -€0.17 |
| €6.17M |
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€0.25€0.00 (0.0%)
co.don AG’s quoted price sits in the lower half of its reported 52-week range, 89.57% below the high.
€0.02€0.00 (0.0%)
BZAM Ltd.’s quoted price sits in the lower half of its reported 52-week range, 88.28% below the high.
€0.12€0.00 (0.0%)
MagForce AG’s quoted price sits in the lower half of its reported 52-week range, 97.04% below the high.
€0.00+€0.00 (+14.29%)
High Fusion Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
€0.87€0.00 (0.0%)
Epigenomics AG’s quoted price sits in the lower half of its reported 52-week range, 45.28% below the high.
$0.00$0.00 (0.0%)
Molecule Holdings Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
€0.05€0.00 (0.0%)
Paion AG’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
€0.02€0.00 (0.0%)
Aladdin Healthcare Technologies SE’s quoted price sits in the lower half of its reported 52-week range, 91.9% below the high.
